VIGL Insider Trading Activity and SEC Form 4 Filings
VIGL insider trading summary
No open-market insider purchases or sales of Vigil Neuroscience, Inc. (VIGL) have been reported on SEC Form 4 in the past 12 months.
Latest VIGL insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 19, 2024 | Haeberlein Samantha L. Budd | Insider | Buy | $21K (12,000 @ $1.71) |
| Dec 19, 2024 | Ivana Magovcevic-Liebisch | President and CEO | Buy | $8K (5,000 @ $1.68) |
| Dec 18, 2024 | Ivana Magovcevic-Liebisch | President and CEO | Buy | $8K (5,000 @ $1.67) |
| Dec 5, 2024 | Ivana Magovcevic-Liebisch | President and CEO | Buy | $12K (5,000 @ $2.34) |
| Nov 20, 2023 | Ivana Magovcevic-Liebisch | President and CEO | Buy | $15K (4,000 @ $3.75) |
| Nov 18, 2022 | Spyros Papapetropoulos | Chief Medical Officer | Sell | $4K (300 @ $14.00) |
| May 17, 2022 | Clay Thorp | Director | Buy | $44K (14,893 @ $2.97) |
| May 16, 2022 | Clay Thorp | Director | Buy | $60K (21,802 @ $2.76) |
| May 5, 2022 | Evan Thackaberry | SVP, Head of Early Development | Buy | $6K (1,500 @ $4.00) |
| May 3, 2022 | Spyros Papapetropoulos | Chief Medical Officer | Buy | $14K (4,000 @ $3.40) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.